© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Fidelity Advisor Biotechnology Fund (FBTTX) stock declined over -0.02%, trading at $43.46 on NASDAQ, down from the previous close of $43.47. The stock opened at $43.47, fluctuating between $43.46 and $43.47 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | 43.47 | 43.47 | 43.46 | 43.46 | 0 |
| Sep 10, 2026 | 43.90 | 43.90 | 43.47 | 43.47 | 0 |
| Sep 09, 2026 | 44.53 | 44.53 | 43.90 | 43.90 | 0 |
| Sep 08, 2026 | 45.08 | 45.08 | 44.53 | 44.53 | 0 |
| Sep 04, 2026 | 45.18 | 45.18 | 45.08 | 45.08 | 0 |
| Sep 03, 2026 | 44.64 | 45.18 | 44.64 | 45.18 | 0 |
| Sep 02, 2026 | 44.64 | 45.20 | 44.64 | 45.20 | 0 |
| Sep 01, 2026 | 44.44 | 44.64 | 44.44 | 44.64 | 0 |
| Aug 31, 2026 | 44.36 | 44.44 | 44.36 | 44.44 | 0 |
| Aug 28, 2026 | 45.72 | 45.72 | 44.36 | 44.36 | 0 |
| Aug 27, 2026 | 46.00 | 46.00 | 45.72 | 45.72 | 0 |
| Aug 26, 2026 | 45.83 | 46.00 | 45.83 | 46.00 | 0 |
| Aug 25, 2026 | 45.83 | 46.58 | 45.83 | 46.58 | 0 |
| Aug 24, 2026 | 46.21 | 46.21 | 45.83 | 45.83 | 0 |
| Aug 21, 2026 | 45.69 | 46.21 | 45.69 | 46.21 | 0 |
| Aug 20, 2026 | 47.32 | 47.32 | 45.69 | 45.69 | 0 |
| Aug 19, 2026 | 44.97 | 47.32 | 44.97 | 47.32 | 0 |
| Aug 18, 2026 | 43.27 | 44.97 | 43.27 | 44.97 | 0 |
| Aug 17, 2026 | 43.27 | 43.86 | 43.27 | 43.86 | 0 |
| Aug 14, 2026 | 43.34 | 43.34 | 43.27 | 43.27 | 0 |
Boston, MA 2210
United States
https://fundresearch.fidelity.com/mutual-funds/summary/315918490877 208 0098This fund primarily allocates its capital to common equities. A substantial portion, specifically at least 80% of its total assets, is dedicated to companies deeply involved in the biotechnology industry. This encompasses businesses engaged in the research, development, manufacturing, and distribution of biotechnological products, services, and processes, as well as those poised to benefit significantly from scientific and technological advancements in the field. Its investments span both domestic and international issuers. To select holdings, the fund employs a rigorous fundamental analysis, evaluating factors such as each company's financial strength, its competitive position within its industry, and broader market and economic conditions. It operates as a non-diversified fund.
| Employees | 0 |
| Beta | 0.62 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | N/A |
| Fiscal Year Ends | N/A |
| Sector | Financial Services |
| Industry | Asset Management |